IGM Biosciences, Inc. (IGMS)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $11k
- Jul 23 · Unusual
- Form 4 sales
- 116
- On record
- Form 144 notices
- 10
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planMay 14 2025
Sold 1,865 shares at $1.12 ($2k)
Weber Steven, PRINCIPAL ACCOUNTING OFFICER
No 10b5-1 planSold 6.5% of holdings ($32k position)27,016 shares left2.4x usual sizeFiling
- 2 Form 4 saleNo planJun 16 +33 days
Sold 951 shares at $1.20 ($1k)
Decker Lisa Lynn, CHIEF BUSINESS OFFICER
No 10b5-1 planSold 1.3% of holdings ($88k position)72,578 shares left0.8x usual sizeFiling
- 3 Form 4 saleNo planJun 16 same day
Sold 1,522 shares at $1.20 ($2k)
Harler Mary Beth, Chief Executive Officer
No 10b5-1 planSold 0.4% of holdings ($408k position)338,181 shares left0.9x usual sizeFiling
- 4 Form 4 saleNo planJun 16 same day
Sold 1,522 shares at $1.20 ($2k)
Tahir Misbah, CHIEF FINANCIAL OFFICER
No 10b5-1 planSold 0.8% of holdings ($216k position)178,802 shares left0.9x usual sizeFiling
- 5 Form 4 saleNo planJun 16 same day
Sold 486 shares at $1.20 ($583)
Weber Steven, PRINCIPAL ACCOUNTING OFFICER
No 10b5-1 planSold 1.8% of holdings ($32k position)26,530 shares left0.5x usual sizeFiling
- 6 Form 4 saleUnusualJul 23 +37 days
Sold 4,409 shares at $1.27 ($6k)
Decker Lisa Lynn, CHIEF BUSINESS OFFICER
No 10b5-1 planSold 6.1% of holdings ($92k position)68,169 shares left3.9x usual sizeFiling
- 7 Form 4 saleUnusualJul 23 same day
Sold 14,501 shares at $1.27 ($18k)
Harler Mary Beth, Chief Executive Officer
No 10b5-1 planSold 4.3% of holdings ($429k position)323,680 shares left9.2x usual sizeFiling
- 8 Form 4 saleUnusualJul 23 same day
Sold 8,741 shares at $1.27 ($11k)
Tahir Misbah, CHIEF FINANCIAL OFFICER
No 10b5-1 planSold 4.9% of holdings ($227k position)170,061 shares left5.6x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (126)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jul 23, 2025 | Tahir Misbah | CHIEF FINANCIAL OFFICER | Form 4 sale | 8,741 | $11k | 4.9% | Unusual | SEC |
| Jul 23, 2025 | Harler Mary Beth | Chief Executive Officer | Form 4 sale | 14,501 | $18k | 4.3% | Unusual | SEC |
| Jul 23, 2025 | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Form 4 sale | 4,409 | $6k | 6.1% | Unusual | SEC |
| Jun 16, 2025 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 486 | $583 | 1.8% | No plan | SEC |
| Jun 16, 2025 | Tahir Misbah | CHIEF FINANCIAL OFFICER | Form 4 sale | 1,522 | $2k | 0.8% | No plan | SEC |
| Jun 16, 2025 | Harler Mary Beth | Chief Executive Officer | Form 4 sale | 1,522 | $2k | 0.4% | No plan | SEC |
| Jun 16, 2025 | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Form 4 sale | 951 | $1k | 1.3% | No plan | SEC |
| May 14, 2025 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 1,865 | $2k | 6.5% | No plan | SEC |
| Mar 14, 2025 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 1,701 | $2k | 5.6% | Unusual | SEC |
| Mar 14, 2025 | Tahir Misbah | CHIEF FINANCIAL OFFICER | Form 4 sale | 7,329 | $9k | 3.9% | Unusual | SEC |
| Mar 14, 2025 | Harler Mary Beth | Chief Executive Officer | Form 4 sale | 7,329 | $9k | 2.1% | Unusual | SEC |
| Mar 14, 2025 | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Form 4 sale | 4,512 | $6k | 5.8% | Unusual | SEC |
| Jan 15, 2025 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 1,122 | $2k | 3.5% | No plan | SEC |
| Dec 16, 2024 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 539 | $4k | 1.7% | No plan | SEC |
| Dec 16, 2024 | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Form 4 sale | 1,063 | $8k | 1.3% | No plan | SEC |
| Dec 16, 2024 | Harler Mary Beth | Chief Executive Officer | Form 4 sale | 1,708 | $13k | 0.5% | No plan | SEC |
| Dec 16, 2024 | Tahir Misbah | CHIEF FINANCIAL OFFICER | Form 4 sale | 1,708 | $13k | 0.9% | No plan | SEC |
| Dec 15, 2024 | Keyt Bruce | Former Officer | Form 144 notice | 18,762 | $135k | Notice | SEC | |
| Dec 14, 2024 | Schwarzer Fred | Former Officer and Director | Form 144 notice | 32,250 | $231k | Notice | SEC | |
| Sep 13, 2024 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 469 | $5k | 1.8% | No plan | SEC |
| Sep 13, 2024 | Takimoto Chris H | CHIEF MEDICAL OFFICER | Form 4 sale | 1,487 | $17k | 1.0% | No plan | SEC |
| Sep 13, 2024 | Tahir Misbah | CHIEF FINANCIAL OFFICER | Form 4 sale | 1,487 | $17k | 1.2% | No plan | SEC |
| Sep 13, 2024 | Schwarzer Fred | CEO AND PRESIDENT | Form 4 sale | 3,946 | $46k | 1.6% | No plan | SEC |
| Sep 13, 2024 | Keyt Bruce | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 1,487 | $17k | 0.6% | No plan | SEC |
| Sep 13, 2024 | Harler Mary Beth | Head, Research & Autoimmunity | Form 4 sale | 1,487 | $17k | 0.9% | No plan | SEC |
| Sep 13, 2024 | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Form 4 sale | 925 | $11k | 1.2% | No plan | SEC |
| Jul 25, 2024 | Hambleton Julie | Director | Form 4 sale | 15,132 | $212k | 88.3% | Routine | SEC |
| Jun 14, 2024 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 495 | $4k | 1.9% | No plan | SEC |
| Jun 14, 2024 | Takimoto Chris H | CHIEF MEDICAL OFFICER | Form 4 sale | 1,570 | $12k | 1.6% | No plan | SEC |
| Jun 14, 2024 | Tahir Misbah | CHIEF FINANCIAL OFFICER | Form 4 sale | 1,570 | $12k | 1.7% | No plan | SEC |
| Jun 14, 2024 | Schwarzer Fred | CEO AND PRESIDENT | Form 4 sale | 4,164 | $32k | 1.6% | No plan | SEC |
| Jun 14, 2024 | Keyt Bruce | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 1,106 | $8k | 0.6% | No plan | SEC |
| Jun 14, 2024 | Harler Mary Beth | Head, Research & Autoimmunity | Form 4 sale | 1,570 | $12k | 1.8% | No plan | SEC |
| Jun 14, 2024 | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Form 4 sale | 977 | $7k | 1.6% | No plan | SEC |
| Mar 14, 2024 | Weber Steven | PRINCIPAL ACCOUNTING OFFICER | Form 4 sale | 993 | $10k | 3.6% | No plan | SEC |
| Mar 14, 2024 | Takimoto Chris H | CHIEF MEDICAL OFFICER | Form 4 sale | 5,424 | $54k | 5.4% | Unusual | SEC |
| Mar 14, 2024 | Tahir Misbah | CHIEF FINANCIAL OFFICER | Form 4 sale | 5,440 | $54k | 5.7% | Unusual | SEC |
| Mar 14, 2024 | Schwarzer Fred | CEO AND PRESIDENT | Form 4 sale | 8,947 | $90k | 4.0% | Unusual | SEC |
| Mar 14, 2024 | Keyt Bruce | CHIEF SCIENTIFIC OFFICER | Form 4 sale | 3,945 | $40k | 2.2% | No plan | SEC |
| Mar 14, 2024 | Decker Lisa Lynn | CHIEF BUSINESS OFFICER | Form 4 sale | 3,376 | $34k | 5.2% | No plan | SEC |
| Mar 13, 2024 | Takimoto Chris H | Officer | Form 144 notice | 6,612 | $66k | Notice | SEC | |
| Mar 13, 2024 | Tahir Misbah | Officer | Form 144 notice | 6,612 | $66k | Notice | SEC | |
| Mar 13, 2024 | Schwarzer Fred | Officer, Director | Form 144 notice | 11,518 | $115k | Notice | SEC | |
| Dec 13, 2023 | Schwarzer Fred | CEO and President | Form 4 sale | 17,576 | $102k | 14.6% | Unusual | SEC |
| Dec 13, 2023 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 7,574 | $44k | 5.5% | Unusual | SEC |
| Dec 13, 2023 | Decker Lisa Lynn | Chief Business Officer | Form 4 sale | 4,369 | $25k | 10.9% | Unusual | SEC |
| Dec 13, 2023 | Schwarzer Fred | Officer, Director | Form 144 notice | 23,262 | $139k | Notice | SEC | |
| Dec 13, 2023 | Keyt Bruce | Officer | Form 144 notice | 10,567 | $63k | Notice | SEC | |
| Dec 13, 2023 | Gauthier George | Officer | Form 144 notice | 5,669 | $34k | Notice | SEC | |
| Dec 13, 2023 | Decker Lisa Lynn | Officer | Form 144 notice | 5,780 | $35k | Notice | SEC | |
| Nov 29, 2023 | Takimoto Chris H | Chief Medical Officer | Form 4 sale | 1,180 | $7k | 2.2% | No plan | SEC |
| Nov 29, 2023 | Gauthier George | Chief Commercial Officer | Form 4 sale | 1,180 | $7k | 2.9% | No plan | SEC |
| Nov 29, 2023 | Decker Lisa Lynn | Chief Business Officer | Form 4 sale | 1,180 | $7k | 2.9% | No plan | SEC |
| Nov 27, 2023 | Tahir Misbah | Chief Financial Officer | Form 4 sale | 1,337 | $7k | 2.6% | No plan | SEC |
| Nov 27, 2023 | Schwarzer Fred | CEO and President | Form 4 sale | 1,337 | $7k | 1.1% | No plan | SEC |
| Nov 27, 2023 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 933 | $5k | 0.7% | No plan | SEC |
| Oct 2, 2023 | Gauthier George | Chief Commercial Officer | Form 4 sale | 935 | $7k | 2.3% | No plan | SEC |
| Oct 2, 2023 | Gauthier George | Officer | Form 144 notice | 935 | $7k | Notice | SEC | |
| Jul 3, 2023 | Gauthier George | Chief Commercial Officer | Form 4 sale | 936 | $9k | 2.3% | No plan | SEC |
| Jun 29, 2023 | Redmile Group, LLC | Director | Form 4 sale | 80,423 | $758k | 2.7% | No plan | SEC |
| May 23, 2023 | Takimoto Chris H | Chief Medical Officer | Form 4 sale | 1,259 | $15k | 2.2% | No plan | SEC |
| May 23, 2023 | Tahir Misbah | Chief Financial Officer | Form 4 sale | 1,259 | $15k | 2.4% | No plan | SEC |
| May 23, 2023 | Schwarzer Fred | CEO and President | Form 4 sale | 1,259 | $15k | 1.0% | No plan | SEC |
| May 23, 2023 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 982 | $12k | 0.7% | No plan | SEC |
| May 23, 2023 | Gauthier George | Chief Commercial Officer | Form 4 sale | 1,259 | $15k | 3.0% | No plan | SEC |
| May 23, 2023 | Decker Lisa Lynn | Chief Business Officer | Form 4 sale | 1,259 | $15k | 3.0% | No plan | SEC |
| Apr 5, 2023 | Gauthier George | Chief Commercial Officer | Form 4 sale | 935 | $12k | 2.7% | No plan | SEC |
| Mar 14, 2023 | Takimoto Chris H | Chief Medical Officer | Form 4 sale | 1,768 | $33k | 5.8% | Plan not stated | SEC |
| Mar 14, 2023 | Tahir Misbah | Chief Financial Officer | Form 4 sale | 1,768 | $33k | 6.5% | Plan not stated | SEC |
| Mar 14, 2023 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,293 | $24k | 1.4% | Plan not stated | SEC |
| Mar 14, 2023 | Gauthier George | Chief Commercial Officer | Form 4 sale | 1,061 | $20k | 5.4% | Plan not stated | SEC |
| Mar 14, 2023 | Decker Lisa Lynn | Chief Business Officer | Form 4 sale | 1,061 | $20k | 6.0% | Plan not stated | SEC |
| Dec 19, 2022 | Tahir Misbah | Chief Financial Officer | Form 4 sale | 6,084 | $119k | 18.3% | Plan not stated | SEC |
| Dec 16, 2022 | Takimoto Chris H | Chief Medical Officer | Form 4 sale | 5,430 | $103k | 15.1% | Plan not stated | SEC |
| Dec 16, 2022 | Schwarzer Fred | CEO and President | Form 4 sale | 12,369 | $235k | 37.8% | Unusual | SEC |
| Dec 16, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 5,371 | $102k | 8.4% | Unusual | SEC |
| Dec 16, 2022 | Gauthier George | Chief Commercial Officer | Form 4 sale | 4,354 | $83k | 18.2% | Plan not stated | SEC |
| Dec 16, 2022 | Decker Lisa Lynn | Chief Business Officer | Form 4 sale | 2,484 | $47k | 12.3% | Plan not stated | SEC |
| Nov 23, 2022 | Takimoto Chris H | Chief Medical Officer | Form 4 sale | 877 | $19k | 2.4% | Plan not stated | SEC |
| Nov 23, 2022 | Tahir Misbah | Chief Financial Officer | Form 4 sale | 877 | $19k | 2.6% | Plan not stated | SEC |
| Nov 23, 2022 | Schwarzer Fred | CEO and President | Form 4 sale | 1,258 | $27k | 3.7% | Plan not stated | SEC |
| Nov 23, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 877 | $19k | 2.2% | Plan not stated | SEC |
| Nov 23, 2022 | Gauthier George | Chief Commercial Officer | Form 4 sale | 1,258 | $27k | 5.0% | Plan not stated | SEC |
| Nov 23, 2022 | Decker Lisa Lynn | Chief Business Officer | Form 4 sale | 1,258 | $27k | 5.8% | Plan not stated | SEC |
| Oct 4, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 25,000 | $571k | 38.8% | Unusual | SEC |
| Sep 8, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 25,000 | $484k | 38.8% | Unusual | SEC |
| Aug 22, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 25,000 | $554k | 38.8% | Unusual | SEC |
| May 26, 2022 | Tahir Misbah | Chief Financial Officer | Form 4 sale | 950 | $16k | 2.7% | Plan not stated | SEC |
| May 24, 2022 | Takimoto Chris H | Chief Medical Officer | Form 4 sale | 938 | $16k | 2.5% | Plan not stated | SEC |
| May 24, 2022 | Schwarzer Fred | CEO and President | Form 4 sale | 1,362 | $23k | 3.9% | Plan not stated | SEC |
| May 24, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 939 | $16k | 2.3% | Plan not stated | SEC |
| May 24, 2022 | Gauthier George | Chief Commercial Officer | Form 4 sale | 1,340 | $23k | 5.0% | Plan not stated | SEC |
| May 24, 2022 | Decker Lisa Lynn | Chief Business Officer | Form 4 sale | 1,362 | $23k | 5.9% | Plan not stated | SEC |
| Apr 6, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 2,500 | $63k | 5.9% | Plan not stated | SEC |
| Mar 30, 2022 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 7,500 | $214k | 15.8% | Unusual | SEC |
| Nov 2, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,326 | $68k | 30.3% | Unusual | SEC |
| Oct 5, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,242 | $80k | 28.9% | Unusual | SEC |
| Sep 3, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,244 | $88k | 28.9% | Unusual | SEC |
| Aug 9, 2021 | Hambleton Julie | Director | Form 4 sale | 1,000 | $80k | 33.3% | Unusual | SEC |
| Aug 4, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,242 | $83k | 28.9% | Unusual | SEC |
| Jul 6, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,247 | $103k | 29.0% | Unusual | SEC |
| Jul 6, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 943 | $78k | 0.8% | Plan not stated | SEC |
| Jun 2, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,245 | $99k | 28.9% | Unusual | SEC |
| Jun 2, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 941 | $74k | 0.8% | Plan not stated | SEC |
| Jun 1, 2021 | Hambleton Julie | Director | Form 4 sale | 2,000 | $160k | 40.0% | Unusual | SEC |
| May 26, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 444 | $31k | 0.4% | Plan not stated | SEC |
| May 5, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 469 | $29k | 0.4% | Plan not stated | SEC |
| May 5, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,243 | $78k | 31.0% | Unusual | SEC |
| Apr 6, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,254 | $103k | 31.2% | Unusual | SEC |
| Apr 6, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 1,222 | $100k | 1.0% | Plan not stated | SEC |
| Mar 2, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,619 | $146k | 36.9% | Unusual | SEC |
| Mar 2, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 1,224 | $110k | 1.0% | Plan not stated | SEC |
| Feb 3, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,619 | $155k | 36.9% | Unusual | SEC |
| Feb 3, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 1,226 | $118k | 1.0% | Plan not stated | SEC |
| Jan 5, 2021 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 2,386 | $197k | 70.2% | Unusual | SEC |
| Jan 5, 2021 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 1,102 | $87k | 0.9% | Plan not stated | SEC |
| Dec 17, 2020 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,618 | $139k | 36.9% | Unusual | SEC |
| Dec 8, 2020 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 1,219 | $111k | 1.0% | Plan not stated | SEC |
| Dec 2, 2020 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 608 | $38k | 0.5% | Plan not stated | SEC |
| Nov 4, 2020 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 605 | $30k | 0.5% | Plan not stated | SEC |
| Oct 2, 2020 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 1,830 | $135k | 1.5% | Unusual | SEC |
| Oct 1, 2020 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,000 | $74k | 34.5% | Unusual | SEC |
| Sep 18, 2020 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 609 | $47k | 0.5% | Plan not stated | SEC |
| Sep 10, 2020 | Keyt Bruce | Chief Scientific Officer | Form 4 sale | 1,000 | $60k | 25.7% | Unusual | SEC |
| Sep 8, 2020 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 602 | $30k | 0.5% | Plan not stated | SEC |
| Aug 27, 2020 | Chen Daniel ShinYu | Chief Medical Officer | Form 4 sale | 605 | $27k | 0.5% | Plan not stated | SEC |